Eribulin

You have access
Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival Benefit
SHOGO NAKAMOTO, MASAHIKO IKEDA, SHINICHIRO KUBO, MARI YAMAMOTO and TETSUMASA YAMASHITA

Anticancer Research June 2021, 41 (6) 3109-3119; DOI: https://doi.org/10.21873/anticanres.15095
You have access
Successful Stabilization of Symptomatic Bone Marrow Metastasis Two Times in a Breast Cancer Patient
HIDEKO AKAGI, AKIHIKO SHIMADA, KENKO CHIN and HIDEHARU DOMOTO

Anticancer Research June 2021, 41 (6) 3139-3144; DOI: https://doi.org/10.21873/anticanres.15099
Open Access
Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model
NATHANIEL F. WU, JUN YAMAMOTO, YUSUKE AOKI, MICHAEL BOUVET and ROBERT M. HOFFMAN

Anticancer Research April 2021, 41 (4) 1779-1784; DOI: https://doi.org/10.21873/anticanres.14943
You have access
Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin
TAKAAKI OBA, KAZUMA MAENO, MAYU ONO, TOKIKO ITO, TOSHIHARU KANAI and KEN-ICHI ITO

Anticancer Research January 2021, 41 (1) 445-452; DOI: https://doi.org/10.21873/anticanres.14794
You have access
Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma
YASUYOSHI SATO, KENJI NAKANO, NAOKI FUKUDA, XIAOFEI WANG, TETSUYA URASAKI, AKIHIRO OHMOTO, MAYU YUNOKAWA, MAKIKO ONO, JUNICHI TOMOMATSU, KEIKO HAYAKAWA, YUKI FUNAUCHI, TAISUKE TANIZAWA, KEISUKE AE, SEIICHI MATSUMOTO and SHUNJI TAKAHASHI

Anticancer Research January 2021, 41 (1) 527-532; DOI: https://doi.org/10.21873/anticanres.14804
You have access
C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin
ATSUSHI SATA, REIKO FUKUI, YOSHIMASA MIYAGAWA, AYAKO BUN, HIROMI OZAWA, YUKIE FUJIMOTO, TOMOKO HIGUCHI, MICHIKO IMAMURA and YASUO MIYOSHI

Anticancer Research July 2020, 40 (7) 4147-4156; DOI: https://doi.org/10.21873/anticanres.14414
You have access
Validation of Systemic and Local Tumour Immune Response to Eribulin Chemotherapy in the Treatment of Breast Cancer
SHINICHIRO KASHIWAGI, YUKA ASANO, WATARU GOTO, KOJI TAKADA, TAMAMI MORISAKI, RIKA KOUHASHI, AKIMICHI YABUMOTO, SAYAKA TANAKA, TSUTOMU TAKASHIMA, MASAHIKO OHSAWA, KOSEI HIRAKAWA and MASAICHI OHIRA

Anticancer Research June 2020, 40 (6) 3345-3354; DOI: https://doi.org/10.21873/anticanres.14317
You have access
Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model
JUN YAMAMOTO, TAKUYA MURATA, NORIHIKO SUGISAWA, TAKASHI HIGUCHI, YOSHIHIKO TASHIRO, HIROTO NISHINO, SACHIKO INUBUSHI, YU SUN, HYEIN LIM, KENTARO MIYAKE, KOICHIRO SHIMOYA, TSUNEHISA NOMURA, JUNICHI KUREBAYASHI, HIROKAZU TANINO, CHIHIRO HOZUMI, MICHAEL BOUVET, SHREE RAM SINGH, ITARU ENDO and ROBERT M. HOFFMAN

Anticancer Research May 2020, 40 (5) 2475-2479; DOI: https://doi.org/10.21873/anticanres.14217
You have access
A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model
HYE IN LIM, JUN YAMAMOTO, SACHIKO INUBUSHI, HIROTO NISHINO, YOSHIHIKO TASHIRO, NORIHIKO SUGISAWA, QUINHONG HAN, YU SUN, HEE JUN CHOI, SEOK JIN NAM, MOON BO KIM, JI SUN LEE, CHIHIRO HOZUMI, MICHAEL BOUVET, SHREE RAM SINGH and ROBERT M. HOFFMAN

Anticancer Research May 2020, 40 (5) 2481-2485; DOI: https://doi.org/10.21873/anticanres.14218
You have access
A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib
JUN YAMAMOTO, TAKUYA MURATA, YOSHIHIKO TASHIRO, TAKASHI HIGUCHI, NORIHIKO SUGISAWA, HIROTO NISHINO, SACHIKO INUBUSHI, YU SUN, HYEIN LIM, KENTARO MIYAKE, ATSUSHI HONGO, TSUNEHISA NOMURA, WATARU SAITOH, TAKUYA MORIYA, HIROKAZU TANINO, CHIHIRO HOZUMI, MICHAEL BOUVET, SHREE RAM SINGH, ITARU ENDO and ROBERT M. HOFFMAN

Anticancer Research May 2020, 40 (5) 2509-2514; DOI: https://doi.org/10.21873/anticanres.14221

Main menu

User menu

Search

Eribulin

Pages